Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study DOI Creative Commons
Yi Peng,

De Pei Wu,

Jing Tang

et al.

Cancer Control, Journal Year: 2025, Volume and Issue: 32

Published: Jan. 1, 2025

Objective To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Materials and Methods We analyzed data from ES-SCLC who achieved stable disease (SD) following initial chemotherapy combined immunotherapy. These subsequently received (MT) a combination of anlotinib PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall (OS), objective response rate (ORR), control (DCR), treatment-related adverse events (AEs). Results Preliminary findings suggest that this regimen is highly effective, median PFS 6 months OS 13.5 months, alongside DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy fewer than three metastatic sites those experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed notable increase the proportion CD8+ T cells peripheral blood post-MT, correlating improved outcomes. imply therapeutic effect MT may be partly due to direct activation cells, producing synergistic anti-tumor response. Despite prevalence AEs, AEs were generally manageable, underscoring anlotinib’s potential context. Conclusion inhibitors offers promising manageable MT, making it viable option achieve SD post-initial therapy. results justify further prospective validate approach.

Language: Английский

Global, regional, and national burden of tracheal, bronchus, and lung cancer and its risk factors from 1990 to 2021: findings from the global burden of disease study 2021 DOI Creative Commons

Ziyu Kuang,

Jiaxi Wang, Kexin Liu

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 75, P. 102804 - 102804

Published: Sept. 1, 2024

Language: Английский

Citations

28
Vaping, Environmental Toxicants Exposure, and Lung Cancer Risk DOI Open Access
Shaimaa A. Shehata, Eman A. Toraih, Ezzat A. Ismail

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(18), P. 4525 - 4525

Published: Sept. 12, 2023

Lung cancer (LC) is the second-most prevalent tumor worldwide. According to most recent GLOBOCAN data, over 2.2 million LC cases were reported in 2020, with an estimated new death incident of 1,796,144 lung cases. Genetic, lifestyle, and environmental exposure play important role as risk factors for LC. E-cigarette, or vaping, products (EVPs) use has been dramatically increasing world-wide. There growing concern that EVPs consumption may increase because contain several proven carcinogenic compounds. However, relationship between not well established. E-cigarette contains nicotine derivatives (e.g., nitrosnornicotine, nitrosamine ketone), heavy metals (including organometal compounds), polycyclic aromatic hydrocarbons, flavorings (aldehydes complex organics). Several toxicants have contribute Proven plausible carcinogens could be physical (ionizing non-ionizing radiation), chemicals (such asbestos, formaldehyde, dioxins), cobalt, arsenic, cadmium, chromium, nickel). Air pollution, especially particulate matter (PM) emitted from vehicles industrial exhausts, linked Although extensive prevention policies smoking reduction strategies adopted globally, dangers remain. Combined, both toxic exposures demonstrate significant synergistic oncogenicity. This review aims analyze current publications on importance pathogenesis

Language: Английский

Citations

28
Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives DOI Creative Commons

Kristina Krpina,

Semir Vranić,

Krešimir Tomić

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(7), P. 1982 - 1982

Published: July 13, 2023

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation, early dissemination, acquired therapy resistance, and poor prognosis. Early diagnosis of SCLC crucial since most patients present with advanced/metastatic disease, limiting the potential for curative treatment. While exhibits initial responsiveness to chemotherapy radiotherapy, treatment resistance commonly emerges, leading a five-year overall survival rate up 10%. New effective biomarkers, detection, advancements in therapeutic strategies are improving rates reducing impact this devastating disease. This review aims comprehensively summarize current knowledge on diagnostic options, well-known emerging discuss future perspectives malignancy.

Language: Английский

Citations

23
The changing landscape of small cell lung cancer DOI
Giordano Fabricio Cittolin‐Santos, Brendan Knapp, Bharath Ganesh

et al.

Cancer, Journal Year: 2024, Volume and Issue: 130(14), P. 2453 - 2461

Published: March 12, 2024

Abstract Background Small‐cell lung cancer (SCLC) is characterized by rapid proliferation and early dissemination. The objective of this study was to examine the demographic trends outcomes in SCLC. Methods authors queried National Cancer Institute's Surveillance, Epidemiology, End Results database assess incidence, demographics, staging, survival for SCLC from 1975 2019. Trends were determined using joinpoint analysis according year diagnosis. Among 530,198 patients with cancer, there 73,362 (13.8%) incidence per 100,000 population peaked at 15.3 1986 followed a decline 6.5 percentage among all tumors increased 13.3% peak 17.5% 1986, declining 11.1% There an median age diagnosis 63 69 years women 31.4% 51.2%. stage IV 58.6% 1988 70.8% 2010, without further increase. most common sites metastasis mediastinal lymph nodes (75.3%) liver (31.6%), bone (23.7%), brain (16.4%). 1‐year 5‐year overall rate 23% 3.6%, respectively, 1975–1979 30.8% 6.8%, 2010–2019. Conclusions gradual decline. Other notable changes include diagnosis, women, improvement has been statistically significant but clinically modest.

Language: Английский

Citations

12
Recent advances and future strategies in first-line treatment of ES-SCLC DOI Open Access

Igor Gómez‐Randulfe,

Rita Leporati,

B. K. Gupta

et al.

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 200, P. 113581 - 113581

Published: Jan. 29, 2024

Language: Английский

Citations

8
Small Cell Lung Cancer—An Update on Chemotherapy Resistance DOI
Ying Qian,

Ruiyun Fan,

Yili Shen

et al.

Current Treatment Options in Oncology, Journal Year: 2024, Volume and Issue: 25(8), P. 1112 - 1123

Published: July 27, 2024

Language: Английский

Citations

8
Understanding the global cancer statistics 2022: growing cancer burden DOI

Yuxi Liu,

Zhibo Zheng

Science China Life Sciences, Journal Year: 2024, Volume and Issue: 67(10), P. 2274 - 2276

Published: Aug. 8, 2024

Language: Английский

Citations

8
Global, regional and national burden of tracheal, bronchus, and lung cancer attributable to ambient particulate matter pollution from 1990 to 2021: an analysis of the global burden of disease study DOI Creative Commons
Jianguo Lü,

Xiangmei Zhao,

Shu Gan

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 9, 2025

The ambient particulate matter pollution may play a critical role in the initiation and development of tracheal, bronchus, lung (TBL) cancer. Up to now, far too little attention has been paid TBL cancer attributable pollution. This study aims assess disease burden global, regional national from 1990 2021 update epidemiology data this disease. Leveraging Global Burden Disease (GBD) study, we analyzed worldwide resulting using indices including disability-adjusted life years (DALYs), age-standardised rate DALYs (ASDR). was further segmented based on variables geographical location, socio-demographic index (SDI), age sex. ASDR per 100,000 population increased by 0.2%[95% UI 0.1 0.3] 79.6[95% 49.0 111.2] Globally. Middle-aged elderly individuals accounted for majority burden, with highest value at 65–69 years. Most concentrated countries High-middle SDI. There positive correlation between due SDI(ρ = 0.66, p < 0.001). East Asia Central Europe exhibited higher observed values than fitted curves, while such as Austraiasia South Western Sub-Saharan Africa had lower curves. Decomposition analysis showed that aging growth were two major drivers increase DALYs. increased, especially regions

Language: Английский

Citations

1
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics DOI Open Access
Subhadeep Das, Shayak Samaddar

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 255 - 255

Published: Jan. 14, 2025

Small-cell lung cancer (SCLC) is a recalcitrant form of cancer, representing 15% cases globally. SCLC classified within the range neuroendocrine pulmonary neoplasms, exhibiting shared morphologic, ultrastructural, immunohistochemical, and molecular genomic features. It marked by rapid proliferation, propensity for early metastasis, an overall poor prognosis. The current conventional therapies involve platinum–etoposide-based chemotherapy in combination with immunotherapy. Nonetheless, emergence therapeutic resistance continues to pose substantial difficulties. profiling uncovers significant chromosomal rearrangements along considerable mutation burden, typically involving functional inactivation tumor suppressor genes TP53 RB1. Identifying biomarkers evaluating new treatments crucial enhancing outcomes patients SCLC. Targeted such as topoisomerase inhibitors, DLL3 HDAC PARP Chk1 etc., have introduced options future applications. In this review, we will attempt outline key pathways that play role development progression SCLC, together comprehensive overview most recent advancements novel targeted treatment strategies, well some ongoing clinical trials against goal improving patient outcomes.

Language: Английский

Citations

1
Oncology: What You May Have Missed in 2024 DOI

Zainab Al Maqrashi,

Sze Wah Samuel Chan, Zeba Siddiqui

et al.

Annals of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Over the past 5 decades, substantial advances in oncology have reshaped cancer care, reflecting dynamic role of internal medicine physicians patients' journey from screening to diagnosis, treatment, and surveillance. This review highlights 10 landmark studies 2024 that address emerging therapies evolving clinical standards. Immunotherapy remains a central focus, with checkpoint inhibitors redefining management solid tumors showing expanded applications across disease sites earlier stages disease. Targeted antibody–drug conjugates, including trastuzumab deruxtecan enfortumab vedotin, are enhancing precision treatment options metastatic cancer. Meanwhile, supportive such as magnetic resonance imaging–guided prostate screening, ponsegromab for cachexia, celiac plexus radiosurgery pain, show enhanced symptom quality life patients. These innovations highlight critical multidisciplinary approaches, where contribute co-management toxicity monitoring, ultimately optimizing patient care. By staying current these developments, positioned navigate complex oncologic ensuring benefits novel maximized while mitigating their challenges.

Language: Английский

Citations

1